JP7517997B2 - プログラニュリンを含む融合タンパク質 - Google Patents

プログラニュリンを含む融合タンパク質 Download PDF

Info

Publication number
JP7517997B2
JP7517997B2 JP2020570444A JP2020570444A JP7517997B2 JP 7517997 B2 JP7517997 B2 JP 7517997B2 JP 2020570444 A JP2020570444 A JP 2020570444A JP 2020570444 A JP2020570444 A JP 2020570444A JP 7517997 B2 JP7517997 B2 JP 7517997B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
identity
progranulin
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020570444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527656A (ja
JP2021527656A5 (cg-RX-API-DMAC7.html
Inventor
パオロ ギルバート ディ
トッド ピー. ローガン
キャサリン エム. モンロー
アンキタ スリヴァスタヴァ
レンゲリッチ ベティーナ ヴァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2021527656A publication Critical patent/JP2021527656A/ja
Publication of JP2021527656A5 publication Critical patent/JP2021527656A5/ja
Application granted granted Critical
Publication of JP7517997B2 publication Critical patent/JP7517997B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020570444A 2018-06-18 2019-06-18 プログラニュリンを含む融合タンパク質 Active JP7517997B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862686579P 2018-06-18 2018-06-18
US62/686,579 2018-06-18
US201862746338P 2018-10-16 2018-10-16
US62/746,338 2018-10-16
PCT/US2019/037695 WO2019246071A1 (en) 2018-06-18 2019-06-18 Fusion proteins comprising progranulin

Publications (3)

Publication Number Publication Date
JP2021527656A JP2021527656A (ja) 2021-10-14
JP2021527656A5 JP2021527656A5 (cg-RX-API-DMAC7.html) 2022-06-27
JP7517997B2 true JP7517997B2 (ja) 2024-07-17

Family

ID=67138158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570444A Active JP7517997B2 (ja) 2018-06-18 2019-06-18 プログラニュリンを含む融合タンパク質

Country Status (17)

Country Link
US (3) US20210284702A1 (cg-RX-API-DMAC7.html)
EP (1) EP3807322A1 (cg-RX-API-DMAC7.html)
JP (1) JP7517997B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210027377A (cg-RX-API-DMAC7.html)
CN (1) CN112424233A (cg-RX-API-DMAC7.html)
AU (1) AU2019288212B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020025306A2 (cg-RX-API-DMAC7.html)
CA (1) CA3101202A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003255A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20081591A (cg-RX-API-DMAC7.html)
IL (1) IL279510B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020012518A (cg-RX-API-DMAC7.html)
PE (1) PE20210323A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020552189A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202011743SA (cg-RX-API-DMAC7.html)
TW (1) TWI874321B (cg-RX-API-DMAC7.html)
WO (1) WO2019246071A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
AU2016270587B2 (en) * 2015-05-29 2020-12-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
SMT202300110T1 (it) 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso
CA3109763A1 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
US20210396772A1 (en) * 2018-10-16 2021-12-23 Denali Therapeutics Inc. Methods for treating and monitoring progranulin-associated disorders
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) * 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CN116133684B (zh) * 2020-05-27 2025-07-18 阿里亚利斯治疗公司 抗人nr1抗体衍生物
US20210393787A1 (en) * 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
KR102666958B1 (ko) * 2020-09-18 2024-05-23 한양대학교 산학협력단 PTPsigma-Fc 융합단백질 및 이를 포함하는 약학 조성물
EP4215607A4 (en) * 2020-09-18 2024-11-06 IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) Ptpsigma-fc fusion protein and pharmaceutical composition comprising same
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
EP4229419A2 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Methods for treating and monitoring frontotemporal dementia
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
AR128003A1 (es) * 2021-12-17 2024-03-20 Denali Therapeutics Inc PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS
WO2023198661A1 (en) * 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
CN119213030A (zh) * 2022-05-16 2024-12-27 戴纳立制药公司 转铁蛋白受体结合结构域和包含其的蛋白
JP2024037109A (ja) * 2022-09-06 2024-03-18 国立大学法人九州大学 分析容器、前処理方法、代謝物解析方法、タンパク質解析方法、及び質量分析方法
EP4630030A2 (en) * 2022-12-06 2025-10-15 ProteinQure Inc. Targeting sortilin
EP4731669A2 (en) * 2023-06-21 2026-04-29 Eli Lilly and Company Compounds for the delivery of granulin across the blood brain barrier
WO2025051953A1 (en) * 2023-09-07 2025-03-13 Novo Nordisk A/S Sortilin-1 binders, constructs and uses thereof
TW202542190A (zh) 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法
WO2025166077A1 (en) * 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
EP4755905A1 (en) 2024-12-05 2026-06-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Truncated progranulin protein and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022175A1 (en) 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
WO2016207240A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3991748A3 (en) * 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
WO2018024162A1 (en) * 2016-08-03 2018-02-08 Sunshine Lake Pharma Co., Ltd. Glp-1 fusion protein comprising mutated immunoglobulin fc portion
EP4628586A3 (en) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Transferrin receptor transgenic models

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022175A1 (en) 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
WO2016207240A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Protein Engineering, Design and Selection,2010年,Vol.23, No.4,PP.289-297

Also Published As

Publication number Publication date
WO2019246071A1 (en) 2019-12-26
PE20210323A1 (es) 2021-02-18
EP3807322A1 (en) 2021-04-21
BR112020025306A2 (pt) 2021-03-09
JP2021527656A (ja) 2021-10-14
CA3101202A1 (en) 2019-12-26
IL279510A (en) 2021-01-31
PH12020552189A1 (en) 2021-06-28
US20210284702A1 (en) 2021-09-16
AU2019288212B2 (en) 2026-04-16
ECSP20081591A (es) 2021-01-29
US20260001925A1 (en) 2026-01-01
CN112424233A (zh) 2021-02-26
AU2019288212A1 (en) 2020-12-03
TWI874321B (zh) 2025-03-01
KR20210027377A (ko) 2021-03-10
CL2020003255A1 (es) 2021-05-28
IL279510B2 (en) 2025-11-01
TW202016152A (zh) 2020-05-01
US20230406898A1 (en) 2023-12-21
IL279510B1 (en) 2025-07-01
SG11202011743SA (en) 2021-01-28
MX2020012518A (es) 2021-02-16

Similar Documents

Publication Publication Date Title
US20260001925A1 (en) Fusion proteins comprising progranulin
US11643446B2 (en) Progranulin variants
JP7854267B2 (ja) 酵素補充療法用酵素を含む融合タンパク質
JP7280241B2 (ja) 操作されたトランスフェリン受容体結合ポリペプチド
JP2025083406A (ja) 操作されたトランスフェリン受容体結合ポリペプチド
WO2020037150A2 (en) Engineered bispecific proteins
JP2020508053A (ja) 操作されたポリペプチド
EA049541B1 (ru) Слитые белки, содержащие програнулин
HK40046687A (en) Fusion proteins comprising progranulin
EA049817B1 (ru) Варианты програнулина
HK40079659A (en) Progranulin variants
HK40031685A (en) Fusion proteins comprising enzyme replacement therapy enzymes
HK40018508A (en) Engineered transferrin receptor binding polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240704

R150 Certificate of patent or registration of utility model

Ref document number: 7517997

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150